2025
Antibody–bottlebrush prodrug conjugates for targeted cancer therapy
Liu B, Nguyen H, Jiang Y, Wang A, Lensch V, Sun Z, Boyer Z, Raftopoulos P, Dai Y, MacNicol P, Wang Y, Jyotsana N, Wang W, Bhagchandani S, Hemdev S, Shieh P, Kristufek S, Boucher M, Downes M, Evans R, MacMillan D, Johnson J. Antibody–bottlebrush prodrug conjugates for targeted cancer therapy. Nature Biotechnology 2025, 1-12. PMID: 40925997, PMCID: PMC12425459, DOI: 10.1038/s41587-025-02772-z.Peer-Reviewed Original ResearchAntibody-drug conjugatesProdrug conjugatesHER2-targeting antibody-drug conjugateDrug mechanismsTargeted cancer therapyDrug-to-antibody ratioDrug mechanism of actionIgG1 monoclonal antibodyMechanism of actionTumor modelCancer therapyTargeted therapeuticsClinical translationMonoclonal antibodiesTraditional antibody-drug conjugateCell uptakeTarget engagementImplementation of a novel interdisciplinary pharmacology curriculum in a hematology/oncology fellowship program.
Forman R, Kwaramba T, Shamilov R, Goldberg S, Lee A, Srikumar T. Implementation of a novel interdisciplinary pharmacology curriculum in a hematology/oncology fellowship program. Journal Of Clinical Oncology 2025, 43: 9028-9028. DOI: 10.1200/jco.2025.43.16_suppl.9028.Peer-Reviewed Original ResearchMechanism of actionCase-basedFellowship programsCancer-directed therapyDrug mechanism of actionTreatment decision makingDosing considerationsPharmacology curriculumToxicity managementTreatment optionsPatient counselingInterdisciplinary patient careLearning science principlesCancer therapeuticsPre-post designCase-based formatPost-lecture surveysThematic qualitative analysisActive learningDrug mechanismsCase-based approachDisease typePost-survey respondentsCase-based curriculum
2023
PI3Kδ Pathway Dysregulation and Unique Features of Its Inhibition by Leniolisib in Activated PI3Kδ Syndrome and Beyond
Cant A, Chandra A, Munro E, Rao V, Lucas C. PI3Kδ Pathway Dysregulation and Unique Features of Its Inhibition by Leniolisib in Activated PI3Kδ Syndrome and Beyond. The Journal Of Allergy And Clinical Immunology In Practice 2023, 12: 69-78. PMID: 37777067, PMCID: PMC10872751, DOI: 10.1016/j.jaip.2023.09.016.Peer-Reviewed Original ResearchConceptsPI3Kδ inhibitorsActivated PI3Kδ SyndromeImmune cell developmentPI3Kδ syndromeSpecific inhibitory propertiesAdverse eventsTreatment optionsPI3Kδ activityHematological malignanciesPathway dysregulationInborn errorsDrug mechanismsGenetic hyperactivationLeniolisibSyndromeΔ isoformsCell developmentInhibitorsInhibitory propertiesΓ isoformsColitisNeutropeniaTolerabilityMalignancyHepatotoxicity
2021
A Pulmonary Vascular Model From Endothelialized Whole Organ Scaffolds
Yuan Y, Leiby KL, Greaney AM, Raredon MSB, Qian H, Schupp JC, Engler AJ, Baevova P, Adams TS, Kural MH, Wang J, Obata T, Yoder MC, Kaminski N, Niklason LE. A Pulmonary Vascular Model From Endothelialized Whole Organ Scaffolds. Frontiers In Bioengineering And Biotechnology 2021, 9: 760309. PMID: 34869270, PMCID: PMC8640093, DOI: 10.3389/fbioe.2021.760309.Peer-Reviewed Original ResearchVascular diseaseEndothelial phenotypeLung vascular diseaseAcute lung injuryPulmonary microvascular functionWhole lung scaffoldsVascular barrier functionLung injuryMicrovascular functionEndothelial cell coverageSingle-cell RNA-sequencing analysisLPS treatmentProinflammatory signalsWhole lungLung endotheliumLung systemVascular barrierOrgan engineering approachesBarrier functionLungWhole-organ scaffoldsVascular structuresDrug mechanismsEndotheliumDiseaseA Practical Clinical Approach to the Management of High-Risk Ulcerative Colitis.
Rubin D, Traboulsi C, Rai V. A Practical Clinical Approach to the Management of High-Risk Ulcerative Colitis. Gastroenterology & Hepatology 2021, 17: 59-66. PMID: 34035764, PMCID: PMC8132723.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsUlcerative colitisDisease activityRecurrent disease activityLong-term remissionManagement of patientsGoal of treatmentPractical clinical approachPatient's risk levelRange of symptomsAbdominal painRectal bleedingFulminant diseasePrognostic factorsSurgical optionsTherapeutic choiceInpatient settingPatientsClinical approachDrug mechanismsDisease responseRemissionColitisTreatmentObjective measuresCritical appraisal
2019
A highly efficient and faithful MDS patient-derived xenotransplantation model for pre-clinical studies
Song Y, Rongvaux A, Taylor A, Jiang T, Tebaldi T, Balasubramanian K, Bagale A, Terzi YK, Gbyli R, Wang X, Fu X, Gao Y, Zhao J, Podoltsev N, Xu M, Neparidze N, Wong E, Torres R, Bruscia EM, Kluger Y, Manz MG, Flavell RA, Halene S. A highly efficient and faithful MDS patient-derived xenotransplantation model for pre-clinical studies. Nature Communications 2019, 10: 366. PMID: 30664659, PMCID: PMC6341122, DOI: 10.1038/s41467-018-08166-x.Peer-Reviewed Original ResearchConceptsPatient-derived xenograftsMyelodysplastic syndromeXenotransplantation modelDysplastic morphologyImmunodeficient murine hostsPre-clinical studiesMDS stem cellsMDS subtypesComprehensive preclinical studiesPreclinical studiesTherapeutic efficacyMurine hostSerial transplantationDrug mechanismsMDS researchStem cell propagationStem cellsDifferentiation potentialHematopoietic stem cell nicheGenetic complexityNovel avenuesStem cell nicheCell propagationDisease representationsImmunodeficient
2017
A systematic analysis of FDA-approved anticancer drugs
Sun J, Wei Q, Zhou Y, Wang J, Liu Q, Xu H. A systematic analysis of FDA-approved anticancer drugs. BMC Systems Biology 2017, 11: 87. PMID: 28984210, PMCID: PMC5629554, DOI: 10.1186/s12918-017-0464-7.Peer-Reviewed Original ResearchConceptsDrug-cancer associationsAnticancer drugsTarget-based drugsEfficient anticancer drugsTarget-based approachCancer typesNew anticancer drugsNovel anticancer drugsClinical trial studyPharmaceutical researchTrial studyMore cancer typesUS FoodDrug AdministrationCytotoxic drugsPatient treatmentPotential candidateDrug mechanismsDrugsDrug repurposingSystematic investigationAssociationDrug targetsTyrosine kinaseSystematic discovery
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply